Search results for "OUTCOME"

showing 10 items of 5148 documents

Repeated kidney re-transplantation—the Eurotransplant experience: a retrospective multicenter outcome analysis

2020

Transplant international (2020). doi:10.1111/tri.13569

re-transplantationOutcome analysis030230 surgeryKidneyALLOCATION0302 clinical medicine3RDfourthKidney transplantationKidneychildGraft SurvivalConfoundinglossSUCCESSrepeatedGRAFT LOSSCOMPETING RISKSTissue Donorsddc:Treatment Outcomesurgical procedures operativemedicine.anatomical_structure030211 gastroenterology & hepatologyOutcome dataLife Sciences & Biomedicinemedicine.medical_specialtykidneyTissue and Organ ProcurementRe transplantation610survival1ST03 medical and health sciencesmedicineHumansddc:6102NDRetrospective StudiesDeceased donorTransplantationScience & Technologybusiness.industrymedicine.diseaseKidney TransplantationSurgeryTransplantationRECIPIENTSgraftSurgeryHuman medicinebusinessthirdSINGLE-CENTER
researchProduct

Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection

2022

Background Some biologics for psoriasis, especially anti-tumor necrosis factor (TNF)-alpha therapies, may re-activate latent tuberculosis (TBC) infection with consequent morbidity and mortality. However, there is a low reported incidence of conversion to positive TBC status among patients with psoriasis treated with second-generation biologic therapies, particularly anti-interleukin (IL)-17 therapies such as secukinumab. Objectives To evaluate the safety profile of secukinumab in psoriasis patients with latent TBC infection. Methods Real-life data were collected by retrospective chart review on patients with moderate-to-severe psoriasis who showed positivity for TBC screening at baseline an…

reactivationBiologicpsoriasis.latent tuberculosis infectionsecukinumabchemoprophylaxisDermatologyBiologicsBiologics; chemoprophylaxis; latent tuberculosis infection; psoriasis; reactivation; secukinumab.Antibodies Monoclonal HumanizedSeverity of Illness IndexTreatment OutcomeLatent TuberculosisIsoniazidHumansPsoriasisTuberculosisRifampinchemoprophylaxiRetrospective Studiespsoriasi
researchProduct

Clinical assessment and comparison of ACL reconstruction using synthetic graft (Neoligaments versus FiberTape).

2021

Background Due to the low potential for primary biological healing of the anterior cruciate ligament (ACL), the most popular approach is currently reconstruction using a graft. Recent research indicates that the technique of strengthening a damaged ligament with synthetic tapes (internal bracing) may be an alternative to reconstructive treatment, especially in cases of partial ACL damage. Objectives To compare and evaluate the possibility of using a synthetic graft (Neoligaments or FiberTape) to treat partial lesions of the ACL. Material and methods This was a retrospective cohort study. Selected from a pool of 128 patients undergoing primary unilateral intra-articular ACL reconstruction du…

reconstructionKnee JointAnterior cruciate ligamentMedicine (miscellaneous)primary repairGroup comparisonKnee JointLachman testGeneral Biochemistry Genetics and Molecular BiologyInternal MedicinemedicineHumansPharmacology (medical)internal bracingAnterior Cruciate LigamentGenetics (clinical)Retrospective StudiesOrthodonticsAnterior Cruciate Ligament Reconstructionbusiness.industryAnterior Cruciate Ligament InjuriesRetrospective cohort studySynthetic graftmusculoskeletal systemathletesmedicine.anatomical_structureTreatment OutcomeReviews and References (medical)LigamentbusinessRange of motionhuman activitiesAdvances in clinical and experimental medicine : official organ Wroclaw Medical University
researchProduct

Off-Adherence Keeping (OAK) observational study: intentional off-adherence immunomodulatory multiple sclerosis treatment

2022

Aims: To evaluate how improved treatment adherence with a lower-frequency regimen/treatment of intramuscular (IM) IFN beta-1a impacts therapeutic effectiveness in relapsing-remitting multiple sclerosis (MS) patients switching from a higher-frequency injectable regimen/treatment. Patients & methods: Italian patients with relapsing-remitting MS and prior poor adherence to high-frequency injectable treatments (n = 181) were followed for 24 months after starting IM IFN beta-1a. Results: During the study, 97.4% of patients were treatment adherent; 22.1% of patients reported a relapse. The estimated probability of remaining relapse-free after 2 years was 78%. A high dropout rate (52.5%) led t…

relapsesMultiple Sclerosis Relapsing-RemittingTreatment Outcomequality of lifeRecurrenceHumansSettore MED/26 - NeurologiaInterferon-betaNeurology (clinical)multiple sclerosistreatment adherenceInterferon beta-1aintramuscular interferon beta-1aNeurodegenerative Disease Management
researchProduct

Efficacy of “Family Connections”, a program for relatives of people with borderline personality disorder, in the Spanish population: study protocol f…

2020

Abstract Background Patients with borderline personality disorder (BPD) experience significant affect regulation difficulties that cause serious consequences in their work, emotional, and social environments. This dysfunctional pattern also produces great suffering and a heavy burden on their relatives. Fortunately, some studies show that treatment of relatives of people with BPD begins to be important in the patients’ recovery and in improving family dynamics. One of the treatments that has obtained the most empirical support is Family connections (FC). This 12-session program is an adaptation of different Dialectical Behavior Therapy strategies. To test the efficacy of FC, five uncontroll…

relativescaregiverslcsh:RC435-571medicine.medical_treatmentDBTInterventionDysfunctional familyBurdenDialectical Behavior TherapyPersonality Disordersburdenlaw.inventionStudy ProtocolRandomized controlled triallawlcsh:PsychiatryIntervention (counseling)Family connectionsmedicineHumansBorderline personality disorderinterventionIntention-to-treat analysisbusiness.industrymedicine.diseasePersonality disordersRelativesDialectical behavior therapyClinical trialPsychiatry and Mental healthTreatment Outcomefamily connectionsCaregiversSpainBorderline personality disorderFamily Relationsbusinessborderline personality disorderClinical psychologyBMC Psychiatry
researchProduct

Effects of Oral Supplementation with Myo-Inositol and D-Chiro-Inositol on Ovarian Functions in Female Long-Term Survivors of Lymphoma: Results from a…

2022

The progressive improvement of lymphoma treatment has led to an important prolongation of patient survival and life expectancy. The principal international scientific societies of oncology now therefore recommend that long-term survivors of lymphoma join fertility programs. Specifically, fertile-age patients should be assisted by a multidisciplinary team, including specialists dedicated to fertility preservation in oncology, in order to support the completion of their reproductive project. In the general population, the use of Myo-Inositol and D-Chiro-Inositol (MI/DCI) has been demonstrated to be an effective choice to treat ovarian dysfunctions, with a consequent improvement in reproductiv…

reproductive outcomesfertility preservationhealth promotionprecision medicineMedicine (miscellaneous)lymphomaprecision medicine; health promotion; Inositol; lymphoma; fertility preservation; reproductive outcomesSettore MED/40 - Ginecologia E OstetriciaInositolInositol; fertility preservation; health promotion; lymphoma; precision medicine; reproductive outcomesJournal of personalized medicine
researchProduct

Maintenance of anticoagulant and antiplatelet agents for patients undergoing vitreoretinal surgery

2009

International audience; Purpose: To establish the prevalence of anticoagulant, aspirin, and clopidogrel use in patients undergoing vitreoretinal surgery, and to compare the outcome of peribulbar anesthesia between users and non-users. Materials and Methods: We conducted a retrospective case series in one academic center between January and June 2009. We analyzed the chart of 239 eyes who underwent posterior segment surgery with peribulbar anesthesia. Data included age, reasons for anticoagulant and/or antiplatelet agents, operative procedure, history of diabetes mellitus, high blood pressure, axial globe length, pre and post operative visual acuity, complications rates during and after anes…

retina[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologygenetic structures[SDV.MHEP.OS] Life Sciences [q-bio]/Human health and pathology/Sensory Organsclinical (human) or epidemiologic studies: outcomes/complications[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organsvitreoretinal surgeryeye diseases[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-α blockers: The GI…

2007

OBJECTIVE: To assess the prevalence of good clinical response and remission in rheumatoid arthritis (RA) patients with longstanding disease treated with anti-tumor necrosis factor-alpha (TNF-alpha) drugs at outpatient clinics. METHODS: Retrospective national study of 14 academic tertiary referral rheumatology medical centers. RA patients with a Disease Activity Score (DAS28) > 3.2 were defined as having active disease and could start TNF-alpha blockers. All patients received one TNF-alpha blocker plus methotrexate (10-20 mg/wk). At the third month the patients were categorized as responders or nonresponders, based on improvement of at least 0.25 of the Health Assessment Questionnaire (HAQ).…

rheumatoid arthritisAdultMaleQuality Assurance Health Carepredictors of remissionTumor Necrosis Factor blockersAntibodies Monoclonal HumanizedSeverity of Illness IndexReceptors Tumor Necrosis FactorEtanerceptArthritis RheumatoidRheumatoid arthritis; Good clinical response; Tumor Necrosis Factor blockersPredictive Value of TestsHumansRheumatoid arthritispredictors of remission; rheumatoid arthritis; tumor necrosis factor-alpha blockersAgedRetrospective StudiesGood clinical responseTumor Necrosis Factor-alphatumor necrosis factor-alpha blockersRemission InductionAdalimumabAntibodies MonoclonalMiddle AgedPrognosisInfliximabLogistic ModelsMethotrexateTreatment Outcomedisability score; good clinical response; remission; rheumatoid arthritis; tumor necrosis factor-α blockersItalyAntirheumatic AgentsImmunoglobulin GFemale
researchProduct

Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side ef…

2007

Objective: To evaluate the efficacy of switching to etanercept treatment in patients with rheumatoid arthritis who already responded to infliximab, but presented side effects. Methods: Charts of 553 patients with rheumatoid arthritis were retrospectively reviewed to select patients who responded to the treatment with infliximab and switched to etanercept because of occurrence of adverse effects. Clinical data were gathered during 24 weeks of etanercept treatment and for the same period of infliximab treatment before infliximab was stopped. Disease Activity Score computed on 44 joints (DAS-44), erythrocyte sedimentation rate (ESR) 1st hour, Visual Analogue Scale (VAS) of pain, Health Assessm…

rheumatoid arthritisMaleConcise ReportArthritisGastroenterologyReceptors Tumor Necrosis FactorEtanerceptEtanerceptArthritis Rheumatoidimmune system diseasesImmunology and AllergyHealth Status Indicatorsskin and connective tissue diseasesmedicine.diagnostic_testbiologyAntibodies MonoclonalMiddle AgedC-Reactive ProteinTreatment OutcomeBiologic agents; etanercept; infliximab; infusion reactionRheumatoid arthritisErythrocyte sedimentation rateAntirheumatic AgentsFemalemedicine.drugmusculoskeletal diseasesAdultmedicine.medical_specialtyVisual analogue scaleImmunologyBlood Sedimentationinfusion reactionGeneral Biochemistry Genetics and Molecular BiologyRheumatologyInternal medicinemedicineHumansAdverse effectRetrospective StudiesChi-Square Distributionbusiness.industryTumor Necrosis Factor-alphaC-reactive proteinetanercept; infliximab; rheumatoid arthritismedicine.diseaseInfliximabInfliximabSurgeryBiologic agentsstomatognathic diseasesImmunoglobulin Gbiology.proteinbusinessinfliximabetanercept
researchProduct

Safety and Tolerance Evaluation of Milk Fat Globule Membrane-Enriched Infant Formulas: A Randomized Controlled Multicenter Non-Inferiority Trial in H…

2014

ObjectiveThis multicenter non-inferiority study evaluated the safety of infant formulas enriched with bovine milk fat globule membrane (MFGM) fractions.MethodsHealthy, full-term infants ( n = 119) age ≤14 days were randomized to standard infant formula (control), standard formula enriched with a lipid-rich MFGM fraction (MFGM-L), or standard formula enriched with a protein-rich MFGM fraction (MFGM-P). Primary outcome was mean weight gain per day from enrollment to age 4 months (non-inferiority margin: –3.0 g/day). Secondary (length, head circumference, tolerability, morbidity, adverse events) and exploratory (phospholipids, metabolic markers, immune markers) outcomes were also evaluated.Res…

safetymedicine.medical_specialtyinfant feedingbusiness.industrygrowthGeneral Engineeringlcsh:RJ1-570lcsh:PediatricsGastroenterologyPrimary outcomeTolerabilityStandard infant formulaformula toleranceInternal medicineMedicineNon inferiority trialGlobules of fatmedicine.symptombusinessAdverse effectMilk fat globuleWeight gainBiomedical engineeringOriginal Researchmilk fat globule membraneClinical Medicine Insights: Pediatrics
researchProduct